{"id":13544,"date":"2016-09-29T15:33:17","date_gmt":"2016-09-29T14:33:17","guid":{"rendered":"https:\/\/faus-moliner.com\/en\/riesgos-los-acuerdos-titulares-patentes-empresas-medicamentos-genericos\/"},"modified":"2016-10-13T10:54:38","modified_gmt":"2016-10-13T09:54:38","slug":"risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies","status":"publish","type":"post","link":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/","title":{"rendered":"Risks in the agreements between patent holders and generic medicinal product companies"},"content":{"rendered":"<p><strong>Background<\/strong><\/p>\n<p>This extensive judgment (+120 pages) addresses the ruling adopted by the European Commission in June 2013, which declared that Lundbeck, Merck, Arrow, Alpharma and Ranbaxy had infringed European rules on competition when agreeing that Lundbeck would provide economic compensation to the manufacturers of generic medicinal products for not marketing Citalopram in certain territories during a specific period of time. These agreements were reflected in patent settlement agreements.<\/p>\n<p><strong>Some ideas on \u201csettlements\u201d<\/strong><\/p>\n<p>This judgment obviously requires an in-depth analysis and raises various question marks, some of which may ultimately be clarified by the Court of Justice in the event of an appeal being filed.<\/p>\n<p>In any case, even if it is just as a preliminary comment, it is worth highlighting some basic ideas in terms of settlement agreements between patent holders and generic medicinal product companies:<\/p>\n<ul>\n<li>Precaution. These agreements may be legitimate, but they may breach competition rules. Any negotiation of such agreement requires a specific analysis from this perspective.<\/li>\n<\/ul>\n<ul>\n<li>Potential competitors. The judgment backs the analysis of the Commission in that the patent holder and any powerful company in the generic medicinal products market are potential competitors, even when patents are in effect, given that the strategies followed by generic medicinal product companies to compete may include (and normally, it is the case) actions to question the validity of patents or to defend their non-infringement; usually willing to assume the investments and risks associated with these actions. Eliminating such competitive pressure by means of this type of agreement, according to the Court, is unacceptable.<\/li>\n<\/ul>\n<ul>\n<li>Is the dispute genuine? All agreements of this type must be thoroughly reviewed. Such an agreement may be acceptable if it seeks to resolve a dispute, even if it involves a payment, if such payment is associated to the strength of the patent, and is needed to achieve an acceptable and legitimate solution for both parties; and does not feature limitations that may delay the market entry of the generic medicinal product.<\/li>\n<\/ul>\n<ul>\n<li>No to mere \u201cpay for delay\u201d settlements. However, an agreement that includes a significant payment to the generic medicinal product company, which remunerates the delay of the market launch of the generic medicinal product and compensates the unearned amounts surrendered by said company as a result of the delay, without resolving the underlying patent dispute, will normally be considered as an agreement that seeks to restrict competition.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Background This extensive judgment (+120 pages) addresses the ruling adopted by the European Commission in June 2013, which declared that Lundbeck, Merck, Arrow, Alpharma and Ranbaxy had infringed European rules on competition when agreeing that Lundbeck would provide economic compensation to the manufacturers of generic medicinal products for not marketing Citalopram in certain territories during&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\" class=\"excerpt-read-more\">Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[72,76,227],"tags":[],"coauthors":[],"class_list":["post-13544","post","type-post","status-publish","format-standard","hentry","category-capsulas-en","category-competition-law","category-competition-law-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner\" \/>\n<meta property=\"og:description\" content=\"Background This extensive judgment (+120 pages) addresses the ruling adopted by the European Commission in June 2013, which declared that Lundbeck, Merck, Arrow, Alpharma and Ranbaxy had infringed European rules on competition when agreeing that Lundbeck would provide economic compensation to the manufacturers of generic medicinal products for not marketing Citalopram in certain territories during... Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\" \/>\n<meta property=\"og:site_name\" content=\"Faus Moliner\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-29T14:33:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-10-13T09:54:38+00:00\" \/>\n<meta name=\"author\" content=\"Jordi Faus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jordi Faus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\"},\"author\":{\"name\":\"Jordi Faus\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260\"},\"headline\":\"Risks in the agreements between patent holders and generic medicinal product companies\",\"datePublished\":\"2016-09-29T14:33:17+00:00\",\"dateModified\":\"2016-10-13T09:54:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"articleSection\":[\"Capsulas\",\"Competition Law\",\"Competition Law\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\",\"url\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\",\"name\":\"Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\"},\"datePublished\":\"2016-09-29T14:33:17+00:00\",\"dateModified\":\"2016-10-13T09:54:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/faus-moliner.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Risks in the agreements between patent holders and generic medicinal product companies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"name\":\"faus-moliner.com\",\"description\":\"Otro sitio realizado con WordPress\",\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/faus-moliner.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\",\"name\":\"Faus Moliner\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"contentUrl\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"width\":400,\"height\":283,\"caption\":\"Faus Moliner\"},\"image\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/2372042\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260\",\"name\":\"Jordi Faus\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/f7cb308a9e6d6fe5434c7ca47ff11be5\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g\",\"caption\":\"Jordi Faus\"},\"description\":\"Jordi Faus graduated in Law at the Autonomous University of Barcelona (1986) and obtained a degree in Advanced Legal European Studies at the College of Europe in Bruges, Belgium (1987). He also has completed an Executive Management Programme at IESE Business School, in Barcelona.\",\"sameAs\":[\"https:\/\/faus-moliner.com\/\"],\"url\":\"https:\/\/faus-moliner.com\/en\/author\/jordi-faus\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/","og_locale":"en_US","og_type":"article","og_title":"Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner","og_description":"Background This extensive judgment (+120 pages) addresses the ruling adopted by the European Commission in June 2013, which declared that Lundbeck, Merck, Arrow, Alpharma and Ranbaxy had infringed European rules on competition when agreeing that Lundbeck would provide economic compensation to the manufacturers of generic medicinal products for not marketing Citalopram in certain territories during... Read More","og_url":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/","og_site_name":"Faus Moliner","article_published_time":"2016-09-29T14:33:17+00:00","article_modified_time":"2016-10-13T09:54:38+00:00","author":"Jordi Faus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jordi Faus","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#article","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/"},"author":{"name":"Jordi Faus","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260"},"headline":"Risks in the agreements between patent holders and generic medicinal product companies","datePublished":"2016-09-29T14:33:17+00:00","dateModified":"2016-10-13T09:54:38+00:00","mainEntityOfPage":{"@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/"},"wordCount":404,"publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"articleSection":["Capsulas","Competition Law","Competition Law"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/","url":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/","name":"Risks in the agreements between patent holders and generic medicinal product companies - Faus Moliner","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/#website"},"datePublished":"2016-09-29T14:33:17+00:00","dateModified":"2016-10-13T09:54:38+00:00","breadcrumb":{"@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/faus-moliner.com\/en\/risks-in-the-agreements-between-patent-holders-and-generic-medicinal-product-companies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/faus-moliner.com\/en\/"},{"@type":"ListItem","position":2,"name":"Risks in the agreements between patent holders and generic medicinal product companies"}]},{"@type":"WebSite","@id":"https:\/\/faus-moliner.com\/en\/#website","url":"https:\/\/faus-moliner.com\/en\/","name":"faus-moliner.com","description":"Otro sitio realizado con WordPress","publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/faus-moliner.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/faus-moliner.com\/en\/#organization","name":"Faus Moliner","url":"https:\/\/faus-moliner.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","contentUrl":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","width":400,"height":283,"caption":"Faus Moliner"},"image":{"@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/2372042\/admin\/"]},{"@type":"Person","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260","name":"Jordi Faus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/f7cb308a9e6d6fe5434c7ca47ff11be5","url":"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g","caption":"Jordi Faus"},"description":"Jordi Faus graduated in Law at the Autonomous University of Barcelona (1986) and obtained a degree in Advanced Legal European Studies at the College of Europe in Bruges, Belgium (1987). He also has completed an Executive Management Programme at IESE Business School, in Barcelona.","sameAs":["https:\/\/faus-moliner.com\/"],"url":"https:\/\/faus-moliner.com\/en\/author\/jordi-faus\/"}]}},"_links":{"self":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts\/13544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/comments?post=13544"}],"version-history":[{"count":0,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts\/13544\/revisions"}],"wp:attachment":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/media?parent=13544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/categories?post=13544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/tags?post=13544"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/coauthors?post=13544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}